Editas Medicine (EDIT) Efficacy Raises The Bigger Question - Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
September 29, 2021 9:00 AM EDTNo serious adverse events or dose-limiting toxicities observed to date
Efficacy signals in the mid-dose cohort provide initial support for clinical benefits
Treatment in the adult high-dose cohort continues and pediatric mid-dose cohort commencing
Data presented in an oral presentation at the International Symposium on Retinal Degeneration
Company to host a webcast today at 11:00 a.m. ET
CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing... More
